CA2539469C - Pyridylacetylenes for use as radiotracers and imaging agents - Google Patents
Pyridylacetylenes for use as radiotracers and imaging agents Download PDFInfo
- Publication number
- CA2539469C CA2539469C CA2539469A CA2539469A CA2539469C CA 2539469 C CA2539469 C CA 2539469C CA 2539469 A CA2539469 A CA 2539469A CA 2539469 A CA2539469 A CA 2539469A CA 2539469 C CA2539469 C CA 2539469C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- methyl
- enone
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012216 imaging agent Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000003839 salts Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 239000012458 free base Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 claims description 8
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000000133 brain stem Anatomy 0.000 claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 2
- 238000002610 neuroimaging Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- ACZNCLRHSFNGTB-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)ethynyl]cyclohex-2-en-1-one Chemical compound CC1=CC=CC(C#CC=2CCCC(=O)C=2)=N1 ACZNCLRHSFNGTB-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- UWOHEEOCHCCCNH-UHFFFAOYSA-N n-[3-[2-(6-methylpyridin-2-yl)ethynyl]cyclohex-2-en-1-ylidene]hydroxylamine Chemical compound CC1=CC=CC(C#CC=2CCCC(C=2)=NO)=N1 UWOHEEOCHCCCNH-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- STDHINPODVHROK-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridine Chemical compound COC1=CC=CC(C#CC=2N=C(C)C=CC=2)=C1 STDHINPODVHROK-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LZIPBJBQQPZLOR-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyloxyethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOS(=O)(=O)C1=CC=C(C)C=C1 LZIPBJBQQPZLOR-UHFFFAOYSA-N 0.000 description 1
- RUFOVPQUNXLVFW-UHFFFAOYSA-N 2-ethynyl-6-methylpyridine Chemical compound CC1=CC=CC(C#C)=N1 RUFOVPQUNXLVFW-UHFFFAOYSA-N 0.000 description 1
- BVSMYYHGYVHWCD-UHFFFAOYSA-N 3-bromocyclohex-2-en-1-one Chemical compound BrC1=CC(=O)CCC1 BVSMYYHGYVHWCD-UHFFFAOYSA-N 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0322612.3A GB0322612D0 (en) | 2003-09-26 | 2003-09-26 | Organic compounds |
| GB0322612.3 | 2003-09-26 | ||
| PCT/EP2004/010743 WO2005030723A1 (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2539469A1 CA2539469A1 (en) | 2005-04-07 |
| CA2539469C true CA2539469C (en) | 2012-06-19 |
Family
ID=29286926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2539469A Expired - Fee Related CA2539469C (en) | 2003-09-26 | 2004-09-24 | Pyridylacetylenes for use as radiotracers and imaging agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8674110B2 (enExample) |
| EP (1) | EP1670762B1 (enExample) |
| JP (1) | JP4965255B2 (enExample) |
| CN (1) | CN100430380C (enExample) |
| AU (2) | AU2004275971B2 (enExample) |
| BR (1) | BRPI0414732A (enExample) |
| CA (1) | CA2539469C (enExample) |
| ES (1) | ES2400713T3 (enExample) |
| GB (1) | GB0322612D0 (enExample) |
| MX (1) | MXPA06003424A (enExample) |
| PL (1) | PL1670762T3 (enExample) |
| PT (1) | PT1670762E (enExample) |
| WO (1) | WO2005030723A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| KR101862626B1 (ko) * | 2010-07-09 | 2018-05-31 | 레코르다티 아일랜드 리미티드 | Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CA2867043A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6843979B2 (en) * | 1999-04-26 | 2005-01-18 | Emory University | 4-haloethenylphenyl tropane:serotonin transporter imaging agents |
| EP1048302A3 (en) * | 1999-04-30 | 2002-07-17 | Pfizer Products Inc. | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease |
| AU5613900A (en) * | 1999-06-30 | 2001-01-31 | Sun Microsystems, Inc. | Customizing web content based on network conditions |
| JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| GB0103045D0 (en) * | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
| JP4070431B2 (ja) * | 2001-07-10 | 2008-04-02 | ジーイー・ヘルスケア・リミテッド | モノアミン再取込み部位のマッピング用ヨウ素付加神経プローブ |
| JP2006513996A (ja) | 2002-10-24 | 2006-04-27 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体 |
-
2003
- 2003-09-26 GB GBGB0322612.3A patent/GB0322612D0/en not_active Ceased
-
2004
- 2004-09-24 US US10/573,162 patent/US8674110B2/en not_active Expired - Fee Related
- 2004-09-24 PT PT47655865T patent/PT1670762E/pt unknown
- 2004-09-24 EP EP04765586A patent/EP1670762B1/en not_active Expired - Lifetime
- 2004-09-24 MX MXPA06003424A patent/MXPA06003424A/es active IP Right Grant
- 2004-09-24 WO PCT/EP2004/010743 patent/WO2005030723A1/en not_active Ceased
- 2004-09-24 CA CA2539469A patent/CA2539469C/en not_active Expired - Fee Related
- 2004-09-24 ES ES04765586T patent/ES2400713T3/es not_active Expired - Lifetime
- 2004-09-24 BR BRPI0414732-4A patent/BRPI0414732A/pt not_active IP Right Cessation
- 2004-09-24 CN CNB2004800273094A patent/CN100430380C/zh not_active Expired - Fee Related
- 2004-09-24 AU AU2004275971A patent/AU2004275971B2/en not_active Ceased
- 2004-09-24 JP JP2006527359A patent/JP4965255B2/ja not_active Expired - Fee Related
- 2004-09-24 PL PL04765586T patent/PL1670762T3/pl unknown
-
2008
- 2008-12-23 AU AU2008261192A patent/AU2008261192B2/en not_active Ceased
-
2014
- 2014-01-24 US US14/162,885 patent/US20140142318A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06003424A (es) | 2006-06-20 |
| US20140142318A1 (en) | 2014-05-22 |
| JP4965255B2 (ja) | 2012-07-04 |
| AU2008261192B2 (en) | 2011-08-04 |
| AU2004275971B2 (en) | 2008-10-02 |
| AU2008261192A1 (en) | 2009-01-22 |
| BRPI0414732A (pt) | 2006-11-21 |
| PT1670762E (pt) | 2013-02-07 |
| WO2005030723A1 (en) | 2005-04-07 |
| US8674110B2 (en) | 2014-03-18 |
| EP1670762B1 (en) | 2012-12-05 |
| AU2004275971A1 (en) | 2005-04-07 |
| GB0322612D0 (en) | 2003-10-29 |
| PL1670762T3 (pl) | 2013-05-31 |
| JP2007506698A (ja) | 2007-03-22 |
| EP1670762A1 (en) | 2006-06-21 |
| CN100430380C (zh) | 2008-11-05 |
| US20090010838A1 (en) | 2009-01-08 |
| CA2539469A1 (en) | 2005-04-07 |
| CN1856468A (zh) | 2006-11-01 |
| ES2400713T3 (es) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008261192B2 (en) | Pyridylacetylenes for use as radiotracers and imaging agents | |
| ES2291323T3 (es) | Antagonistas de receptores de trombina. | |
| KR100272614B1 (ko) | 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체 | |
| Hintermann et al. | ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies | |
| CN101967105B (zh) | 具有抗癌活性的β-羟基保护的双癸基季铵盐及制备方法 | |
| JPS60112793A (ja) | ６―ビニル―フロー（３，４―ｃ）―ピリジン誘導体，その製造法及びそれを含有する利尿組成物 | |
| DE2501468A1 (de) | Heteroaroylheterocyclen | |
| CA1246077A (en) | Vinyl carboxylic acid derivatives, their production and use | |
| EP0114573B1 (de) | Imidazo(1,5-a)pyridin-Derivate | |
| PT91326A (pt) | Processo para a preparacao de derivados de imidazo-{4,5-b}piridina | |
| JP2007506698A5 (enExample) | ||
| IE883136L (en) | Ó(2)-adreno receptor antagonists | |
| Mátyus et al. | Novel pyridazino [4, 5-b][1, 5] oxazepines and-thiazepines as 5-HT1A receptor ligands | |
| EP0966440B1 (en) | Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof | |
| CN113307758A (zh) | 一种医用放射性同位素标记的p2x7受体靶向探针前体 | |
| Nakamura et al. | Simple and efficient preparation of sterically protected 1, 4-diphosphafulvenes | |
| KR100256866B1 (ko) | 디엘-무스콘으로부터 엘-무스콘과 디-무스콘의 제조방법 | |
| CN113583012B (zh) | 一种吡喃并[4,3-b]吡啶-2,7-二酮化合物的合成方法 | |
| CN112824388B (zh) | 一种诺氟沙星的丙烯酮衍生物及其制备方法和应用 | |
| JP4212123B2 (ja) | ２，４′―ジピリジル誘導体の製造方法、分離方法並びにベンゾオキサゼピン誘導体およびその塩の製造方法 | |
| CN121974971A (en) | Tanshinone IIA derivative and application thereof | |
| CN106905205A (zh) | 一种一步构筑c‑o和c‑s键双官能化产物及其制备方法 | |
| JPS6216462A (ja) | ４−シアノピペリジン誘導体 | |
| KR20260061203A (ko) | 거대고리 화합물 및 그 용도 | |
| JPH0395138A (ja) | ３―メチルヘプタン酸の光学分割法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150924 |